OriCAR-017 Clinical Data Selected for Oral Presentation at EHA 2022 Congress
OriCell Therapeutics announced the newest data from a Phase I study evaluating OriCAR-017 in patients with Relapsed/Refractory Multiple Myeloma (POLARIS) has been accepted by the 27th European Hematology Association Congress, and detailed information will be presented in an oral seesion. OriCAR-017 is a CAR-T product with a novel target based on OriCell's independently developed Ori®Ab and Ori®CAR technology platform.
OriCAR-017 a reserve CAR-T product with a novel target based on OriCell's independently developed Ori®Ab and Ori®CAR technology platform. Currently the product under investigator instigated trial(IIT) in China by RRMM researchers to evaluate safety and effectiveness.
About Ori®CAR Technology Platform
An autologous GPRC5D-directed CAR T cell with a memory and anti-exhaustion T cells phenotype on the basis of the standard second generation CAR T cell, which improves the expansion and durability of CAR-T post-transfusion.
About OriCell Therapeutics
Founded in 2015, OriCell Therapeutics aims to develop novel immuno-therapies to satisfy the globally unmet clinical needs. OriCell have constructed 4 major patented technology platforms: Ori®Ab antibody discovery technology platform, Ori®CAR CAR-T technology platform with high memory and high vitality, Ori®TIL stable and controllable cell culture platform for efficient expansion, and Ori®UCAR general-purpose, convenient and efficient CAR-T technology platform.